SWTX SpringWorks Therapeutics Inc

STAMFORD, Conn., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® ( nirogacestat ) , an oral gamma secretase inhibitor for ...

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile Long-term continuous OGSIVEO treatment for up to 4 years was associated ...

- Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...

STAMFORD, Conn., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission ( EC ) granted marketing authorization for OGSIVEO® ( nirogacestat ) , an oral gamma secretase inhibitor, as ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...